Concord Biotech enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024


12,874	—	—	—
446	414	317	259
−3.9	−1.9	0.0	—
0.0	0.0	0.4	6.2
12,425	—	—	—
−446	−414	−317	−253
₹1,187.63	—	—	—

2,072	2,015	1,813	1,533
0.0%	0.0%	0.0%	0.4%

10.62×	—	—	—
30.73×	—	—	—
37.71×	—	—	—
72.35×	—	—	—
1,170	1,055	1,200	1,017
404	367	506	432
330	293	452	378
—	267	245	265
172	172	133	180
—	172	133	179
—	95.2	111	85.7

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

CONCORDBIO₹1,230.60

Concord Biotech Ltd.

· Pharma & Health

₹ CrorePeersBIOCON DIVISLAB CAPLIPOINT EMCURE BLUEJET ERIS GRANULES ACUTAASMcap ₹12,874 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	12,874.0
- Cash, Equiv & ST Investments	—	258.8	317.4	414.2	445.6
+ Minority Interest	—	—	0.0	-1.9	-3.9
+ Total Debt	—	6.2	0.4	0.0	0.0
Enterprise Value	—	—	—	—	12,424.5
Net Debt (memo)	—	-252.6	-317.1	-414.2	-445.6
EV per Share	—	—	—	—	1,187.63

Total Capital	—	1,532.9	1,813.1	2,015.1	2,071.9
Total Debt/Total Capital	—	0.41	0.02	0.00	0.00

EV/Sales	—	—	—	—	10.62
EV/EBITDA	—	—	—	—	30.73
EV/EBIT	—	—	—	—	37.71
EV/Free Cash Flow	—	—	—	—	72.35
Reference Items — Trailing FY Values
Sales	—	1,016.9	1,200.1	1,054.9	1,170.4
EBITDA	—	431.6	506.3	367.4	404.3
EBIT	—	378.0	452.0	292.9	329.5
Operating Cash Flow	—	265.5	244.5	266.9	—
Free Cash Flow	—	179.8	133.3	171.7	171.7
FCFF (free cash flow to the firm)	—	179.2	133.3	171.7	—
Capital Expenditure	—	85.7	111.2	95.2	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.